BFTC-905 Cells
CAD$966.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The BFTC-905 cell line is a human transitional cell carcinoma (TCC) model derived from a high-grade, papillary bladder tumor in a female patient. It was established to represent aggressive bladder cancer and has been used in cytogenetic and molecular profiling studies to understand bladder tumor biology and therapeutic vulnerabilities. BFTC-905 exhibits a highly complex and rearranged karyotype, which includes multiple chromosomal abnormalities typical of advanced bladder cancers. These include non-random alterations such as deletions of 8p, duplications of 8q, and gains in chromosomes 7 and 20, features often linked to disease progression and poor prognosis in urothelial carcinoma. Extensive characterization using multi-color fluorescence in situ hybridization (M-FISH) has revealed numerous structural rearrangements in BFTC-905, including interchromosomal translocations and deletions affecting loci with potential relevance to tumor suppressor loss. Specifically, BFTC-905 displays a deletion of chromosome 8p21, a region frequently lost in aggressive TCC and associated with tumor suppressor genes. This cytogenetic complexity provides a valuable opportunity for dissecting gene function in the context of genomic instability, a hallmark of late-stage bladder cancers. BFTC-905 has also been included in large-scale pharmacogenomic studies such as the Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (GDSC). These resources have confirmed the molecular fidelity of BFTC-905 to primary bladder tumors and have enabled its use in predictive modeling of anticancer drug responses. Its multi-omics profile-including gene expression, mutation status, copy number variation, and DNA methylation-makes it a powerful model for investigating bladder cancer-specific therapeutic targets and resistance mechanisms. |
|---|---|
| Organism | Human |
| Tissue | Urinary bladder |
| Disease | Bladder carcinoma |
| Synonyms | BFTC 905, BFTC905, Black Foot disease Transitional Carcinoma 905 |
Characteristics
| Age | 51 years |
|---|---|
| Gender | Female |
| Ethnicity | Chinese |
| Morphology | Epithelial |
| Cell type | Epithelial |
| Growth properties | Adherent |
Regulatory Data
| Citation | BFTC-905 (Cytion catalog number 305749) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1083 |
Biomolecular Data
| Isoenzymes | G6PD; MD; LD |
|---|---|
| Viruses | Reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, HHV-8 -, HIV-1 -, HIV-2 -, HTLV-1/2 -, MLV -, SMRV - |
| Mutational profile | Mutation: NRAS, Simple, p.Gln61Leu (c.182A>T), Heterozygous (Cosmic-CLP=910926), TP53, Simple, c.673-2A>T (IVS6-2A>T), Homozygous, Note=Splice acceptor mutation (Cosmic-CLP=910926) |
Handling
| Culture Medium | DMEM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 3.7 g/L NaHCO3, w: 1.0 mM Sodium pyruvate (Cytion article number 820300a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Doubling time | 60-70 hours |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Seeding density | 1 to 3 x 104 cells/cm2 |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305749-070426 | Certificate of Analysis | 15. May. 2026 | 305749 |